A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer (ASPEN-06)
Phase 2
Suspended
- Conditions
- gastric/gastroesophageal junction adenocarcinoma
- Registration Number
- JPRN-jRCT2031220162
- Lead Sponsor
- Fanning Philip
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
-Adequate Bone Marrow Function.
-Adequate Renal and Liver Function.
-Adequate Performance Status.
Exclusion Criteria
-Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
-Prior treatment with any anti-CD47 or anti-SIRP alpha agent.
-Prior treatment with ramucirumab.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase 2:<br>-Percentage of patients with objective response per RECIST 1.1<br>Phase 3: <br>-Overall Survival
- Secondary Outcome Measures
Name Time Method